Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

Harness Health Pharmacy

Actemra

Afinitor

Alecensa

Alunbrig

Aranesp

Benlysta

Cabometyx

Calquence

Cinqair

Copiktra

Cosentyx

Daraprim

Dysport

Enbrel

Endari

Enspryng

Esbriet

Entyvio

Erleada

Exjade

Farydak

Fasenra

Gilotrif

Idhifa

Ilaris

Ilumya

Inqovi

Inrebic

Iressa

Jakafi

Kepivance

Khapzory

Koselugo

Lonsurf

Lucentis

Lynparza

Mayzent

Mekinist

Nexavar

Nplate

Nubeqa

Ocrevus

Odomzo

Olumiant

Onureg

Orgovyx

Piqray

Promacta

Retacrit

Retevmo

Rituxan

Rozlytrek

Rubraca

Rylaze

Stelara

Stivarga

Sylvant

Synagis

Tabrecta

Tafinlar

Tagrisso

Tarceva

Targretin

Tasigna

Tavalisse

Temodar

Tibsovo

Trelstar

Tykerb

Tymlos

Udenyca

Verenzio

Vidaza

Vitravki

Votrient

Vpriv

Xolair

Xospata

Xtandi

Yonsa

Zejula

Zeposia

Zykadia

Rinvoq | Harness Health Pharmacy

Does Harness Health Pharmacy work closely with Rinvoq and AbbVie Inc.?

Does Harness Health Pharmacy offer services for Rinvoq patients?

What conditions does Harness Health Pharmacy support?

How does Harness Health Pharmacy help with insurance?